7JK.F EQL PHARMA AB

Healthcare Pharmaceuticals Frankfurt Exchange
2.23 EUR
Close of Nov 11, 2026
1.66 6.26
Market cap
EUR 66.0M
P/E
-
P/B
2.85x
ROE
-3.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.

Is 7JK.F undervalued?

Graham number

The Graham number of EQL PHARMA AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

EQL PHARMA AB fundamental analysis

No fundamental analysis for EQL PHARMA AB yet.

EQL PHARMA AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About EQL PHARMA AB

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers prescription drugs, including hospital products. EQL Pharma AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.

Full company profile